Brigatinib(Alunbrig)

Brigatinib is a targeted therapy drug whose main component is a tyrosine kinase inhibitor.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Brigatinib Drug News

FDA Approves Alunbrig (Brigatinib): Takeda Announces Accelerated Approval for ALK+ Metastatic NSCLC

FDA Accelerated Approval AnnouncementCambridge, Mass. and Osaka, Japan – April 28, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) today anno···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 71
FDA Approves Takeda’s Alunbrig (Brigatinib) as First-Line Therapy for ALK+ Metastatic NSCLC

FDA Approval AnnouncementCAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE) May 22, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 76

Bigbear Pharmaceutical